AORT's FDA approval for AMDS removes a key hospital adoption hurdle and opens access to an estimated $150 million annual U.S. market.
Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript
Artivion NYSE: AORT executives said the company delivered double-digit revenue and adjusted EBITDA growth in the first quarter of 2026, while also lowering its full-year revenue outlook due primarily to softer stent graft trends and timing around U.S. AMDS account stocking.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 126 | $3,551.63 | $3,034.08 | -$517.55 | -14.57% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 130 | $5,458.44 | $3,109.6 | -$2,348.84 | -43.03% |
| BG Bart Gancher Intech Investment Management LLC | 13,620 | $621,208.2 | $326,199 | -$295,009.2 | -47.49% |
Juniper Investment Company Juniper Investment Company LLC | 1.19M | $28.21M | $28.48M | $271,155.69 | 0.96% |
| MD Michelle Dubey Yousif Capital Management LLC | 11,327 | $232,488.11 | $275,359.37 | $42,871.26 | 18.44% |
| Health Care Equipment & Supplies Industry | Healthcare Sector | James Patrick Mackin CEO | NYSE Exchange | 228903100 CUSIP |
| US Country | 1,600 Employees | 12 Mar 2014 Last Dividend | 28 Dec 2000 Last Split | - IPO Date |
Artivion, Inc., initially known as CryoLife, Inc., before its name change in January 2022, is a prominent entity in the medical devices and implantable human tissues sector, with operations extending globally. Founded in 1984 and based in Kennesaw, Georgia, the company is adept at manufacturing, processing, and distributing a wide array of medical devices. These products are designed for use in various medical procedures, including cardiac, vascular, neurologic, and pulmonary operations. Artivion, Inc. caters to a diverse clientele, including physicians, hospitals, and other healthcare facilities, with its offerings significantly influencing the practices of cardiac, vascular, thoracic, and general surgeons across the world.